Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Humira's early-line growth threatens Enbrel's future uptake in psoriatic arthritis

Humira's early-line growth threatens Enbrel's future uptake in psoriatic arthritis

Study reports high prevalence of vitamin D insufficiency in patients with psoriatic arthritis

Study reports high prevalence of vitamin D insufficiency in patients with psoriatic arthritis

Positive results from etanercept pilot study against dermatomyositis

Positive results from etanercept pilot study against dermatomyositis

Humira defect lawyers file suit against Abbott Laboratories in federal court

Humira defect lawyers file suit against Abbott Laboratories in federal court

NYU Langone webinar discusses advances in the treatment of RA

NYU Langone webinar discusses advances in the treatment of RA

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Psoriasis patients still need long-established treatment alternatives

Psoriasis patients still need long-established treatment alternatives

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Researchers create protein molecule for new anti-inflammatory therapies

Researchers create protein molecule for new anti-inflammatory therapies

American Academy of Dermatology releases final guidelines of care for psoriasis

American Academy of Dermatology releases final guidelines of care for psoriasis

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Boehringer Ingelheim to acquire Amgen's Fremont California development and manufacturing facility

Boehringer Ingelheim to acquire Amgen's Fremont California development and manufacturing facility

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

IFPA announces winner of Under the Spotlight Award for psoriasis documentary

IFPA announces winner of Under the Spotlight Award for psoriasis documentary

SIMPONI injection improves inflammation, structural damage in RA patients

SIMPONI injection improves inflammation, structural damage in RA patients